首页 > 最新文献

ACS Applied Energy Materials最新文献

英文 中文
eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K/AKT signaling pathway. eIf3a 通过 PI3K/AKT 信号通路介导结直肠癌的恶性生物学行为。
IF 3.6 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-05-23 DOI: 10.1080/15384047.2024.2355703
Chao Huo, Disheng Wu, Xiaodan Li, Yan Zhang, Baoguang Hu, Taoming Zhang, Jianwei Ren, Tianbao Wang, Yi Liu

Colorectal cancer (CRC) is among the most common gastrointestinal malignancies worldwide. eIF3a is highly expressed in a variety of cancer types, yet its role in CRC remains unclear. We introduced ectopic eIF3a expression in CRC cells to investigate its relevance to various malignant behaviors. Further, we silenced eIF3a to explore its effect on tumor growth in a nude mouse tumor xenograft model. Finally, the molecular mechanisms through which eIF3a regulates malignancy in CRC cells were explored through bioinformatics analysis combined with the use of a specific PI3K inhibitor (LY294002). eIF3a was highly expressed in the peripheral blood and cancer tissue of CRC patients. Malignancy and tumor growth were significantly inhibited by silencing eIF3a, while overexpression promoted malignant behaviors, with a positive correlation between PI3K/AKT activation and eIF3a expression. Taken together, eIF3a plays an oncogenic role in CRC by regulating PI3K/AKT signaling and is a potential biomarker for CRC diagnosis and prognostic monitoring.

大肠癌(CRC)是全球最常见的胃肠道恶性肿瘤之一。eIF3a在多种癌症类型中高度表达,但它在CRC中的作用仍不清楚。我们在 CRC 细胞中引入了 eIF3a 的异位表达,以研究它与各种恶性行为的相关性。此外,我们还在裸鼠肿瘤异种移植模型中沉默了 eIF3a,以探讨其对肿瘤生长的影响。最后,我们通过生物信息学分析,结合使用特异性 PI3K 抑制剂(LY294002),探讨了 eIF3a 调节 CRC 细胞恶性程度的分子机制。沉默eIF3a能显著抑制恶性肿瘤的发生和生长,而过表达则会促进恶性行为,PI3K/AKT的激活与eIF3a的表达呈正相关。综上所述,eIF3a通过调控PI3K/AKT信号在CRC中发挥致癌作用,是CRC诊断和预后监测的潜在生物标志物。
{"title":"eIf3a mediates malignant biological behaviors in colorectal cancer through the PI3K/AKT signaling pathway.","authors":"Chao Huo, Disheng Wu, Xiaodan Li, Yan Zhang, Baoguang Hu, Taoming Zhang, Jianwei Ren, Tianbao Wang, Yi Liu","doi":"10.1080/15384047.2024.2355703","DOIUrl":"10.1080/15384047.2024.2355703","url":null,"abstract":"<p><p>Colorectal cancer (CRC) is among the most common gastrointestinal malignancies worldwide. eIF3a is highly expressed in a variety of cancer types, yet its role in CRC remains unclear. We introduced ectopic eIF3a expression in CRC cells to investigate its relevance to various malignant behaviors. Further, we silenced eIF3a to explore its effect on tumor growth in a nude mouse tumor xenograft model. Finally, the molecular mechanisms through which eIF3a regulates malignancy in CRC cells were explored through bioinformatics analysis combined with the use of a specific PI3K inhibitor (LY294002). eIF3a was highly expressed in the peripheral blood and cancer tissue of CRC patients. Malignancy and tumor growth were significantly inhibited by silencing eIF3a, while overexpression promoted malignant behaviors, with a positive correlation between PI3K/AKT activation and eIF3a expression. Taken together, eIF3a plays an oncogenic role in CRC by regulating PI3K/AKT signaling and is a potential biomarker for CRC diagnosis and prognostic monitoring.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"25 1","pages":"2355703"},"PeriodicalIF":3.6,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11123456/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141086889","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Healthcare workers' willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo. 刚果民主共和国医护人员接受 COVID-19 强化剂量的意愿及相关因素。
IF 4.8 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-05-23 DOI: 10.1080/21645515.2024.2357214
Bertin Mindje Kolomba, Francois Kalenga Luhembwe, Deca Blood Banza Ndala, Pacifique Kanku Wa Ilunga, Paul Ciamala Mukendi, Amide Ngongo Kitenge, John Ngoy Lumbule, Elie Kilolo Ngoy, Antoine Umba Ilunga, Judith Mbidi Miema, Christelle Kalikat Mwavita, Guillaume Ngoy Mwamba, Aime Cikomola Wa Bene, Audry Mulumba Wakamba, Alain Ngashi Ngongo, Michel Kabamba Nzaji

The COVID-19 booster dose is considered an important adjunct for the control of the COVID-19 pandemic due to reports of reduced immunity in fully vaccinated individuals. The aims of this study were to assess healthcare workers' intention to receive the booster dose of COVID-19 vaccine and to identify predictive factors among healthcare workers. A cross-sectional study was conducted among healthcare workers selected in two provinces, Kasai Oriental, and Haut-Lomami. Data were collected using a questionnaire administered through structured face-to-face interviews, with respondents using a pre-tested questionnaire set up on the Open Data Kit (ODK Collect). All data were analyzed using SPSS v26.0 (IBM Corporation, Armonk, NY, USA). Vaccination coverage for COVID-19, considering declarations by health workers, is around 85.9% for the province of Kasai Oriental and 85.8% for Haut-Lomami. A total of 975 responses were collected, 71.4% of health workers at Kasai Oriental and 66.4% from Haut-Lomami declared a definite willingness to receive a COVID-19 vaccine booster. The duration of protection was the main reason for accepting a booster COVID-19 dose for 64.6% of the respondents. Logistic regression analysis showed that having chronic diseases (aOR = 2.95 [1.65-5.28]), having already received one of the COVID-19 vaccines (aOR = 2.72 [1.43-5. 19]); the belief that only high-risk individuals, such as healthcare professionals and elderly people suffering from other illnesses, needed a booster dose (aOR = 1.75 [1.10-2.81]). Considering the burden of COVID-19, a high acceptance rate for booster doses could be essential to control the pandemic. Our results are novel and could help policymakers design and implement specific COVID-19 vaccination programs to reduce reluctance to seek booster vaccination.

由于有报道称完全接种过疫苗的人免疫力下降,COVID-19加强剂被认为是控制COVID-19大流行的重要辅助手段。本研究旨在评估医护人员接种 COVID-19 加强剂疫苗的意愿,并确定医护人员的预测因素。研究在东开赛省和上洛马米省两个省份的医护人员中进行了横断面研究。通过结构化面对面访谈的方式进行问卷调查,受访者使用在开放数据工具包(ODK Collect)上设置的预检问卷收集数据。所有数据均使用 SPSS v26.0(IBM 公司,美国纽约阿蒙克)进行分析。根据卫生工作者的申报,COVID-19 疫苗接种覆盖率在东开赛省约为 85.9%,在上洛马米省约为 85.8%。共收集到 975 份答复,71.4% 的东开赛省卫生工作者和 66.4% 的上洛马米省卫生工作者明确表示愿意接种 COVID-19 强化疫苗。64.6%的受访者接受 COVID-19 强化接种的主要原因是保护期。逻辑回归分析表明,患有慢性疾病(aOR = 2.95 [1.65-5.28])、已经接种过一种 COVID-19 疫苗(aOR = 2.72 [1.43-5.19])、认为只有高危人群(如医护人员和患有其他疾病的老人)才需要接种加强剂(aOR = 1.75 [1.10-2.81])。考虑到 COVID-19 带来的负担,较高的加强剂量接受率对于控制大流行至关重要。我们的研究结果很新颖,可以帮助政策制定者设计和实施特定的COVID-19疫苗接种计划,以减少不愿意接种强化疫苗的情况。
{"title":"Healthcare workers' willingness to receive COVID-19 booster dose and associated factors in the Democratic Republic of the Congo.","authors":"Bertin Mindje Kolomba, Francois Kalenga Luhembwe, Deca Blood Banza Ndala, Pacifique Kanku Wa Ilunga, Paul Ciamala Mukendi, Amide Ngongo Kitenge, John Ngoy Lumbule, Elie Kilolo Ngoy, Antoine Umba Ilunga, Judith Mbidi Miema, Christelle Kalikat Mwavita, Guillaume Ngoy Mwamba, Aime Cikomola Wa Bene, Audry Mulumba Wakamba, Alain Ngashi Ngongo, Michel Kabamba Nzaji","doi":"10.1080/21645515.2024.2357214","DOIUrl":"10.1080/21645515.2024.2357214","url":null,"abstract":"<p><p>The COVID-19 booster dose is considered an important adjunct for the control of the COVID-19 pandemic due to reports of reduced immunity in fully vaccinated individuals. The aims of this study were to assess healthcare workers' intention to receive the booster dose of COVID-19 vaccine and to identify predictive factors among healthcare workers. A cross-sectional study was conducted among healthcare workers selected in two provinces, Kasai Oriental, and Haut-Lomami. Data were collected using a questionnaire administered through structured face-to-face interviews, with respondents using a pre-tested questionnaire set up on the Open Data Kit (ODK Collect). All data were analyzed using SPSS v26.0 (IBM Corporation, Armonk, NY, USA). Vaccination coverage for COVID-19, considering declarations by health workers, is around 85.9% for the province of Kasai Oriental and 85.8% for Haut-Lomami. A total of 975 responses were collected, 71.4% of health workers at Kasai Oriental and 66.4% from Haut-Lomami declared a definite willingness to receive a COVID-19 vaccine booster. The duration of protection was the main reason for accepting a booster COVID-19 dose for 64.6% of the respondents. Logistic regression analysis showed that having chronic diseases (aOR = 2.95 [1.65-5.28]), having already received one of the COVID-19 vaccines (aOR = 2.72 [1.43-5. 19]); the belief that only high-risk individuals, such as healthcare professionals and elderly people suffering from other illnesses, needed a booster dose (aOR = 1.75 [1.10-2.81]). Considering the burden of COVID-19, a high acceptance rate for booster doses could be essential to control the pandemic. Our results are novel and could help policymakers design and implement specific COVID-19 vaccination programs to reduce reluctance to seek booster vaccination.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2357214"},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11135840/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141089161","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Circ_RPPH1 facilitates progression of breast cancer via miR-1296-5p/TRIM14 axis. Circ_RPPH1 通过 miR-1296-5p/TRIM14 轴促进乳腺癌的进展。
IF 4.4 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-05-30 DOI: 10.1080/15384047.2024.2360768
Jing Jiang, Shenghong Shi, Wei Zhang, Chao Li, Long Sun, Qidong Ge, Xujun Li

Circular RNA Ribonuclease P RNA Component H1 (circ_RPPH1) and microRNA (miRNA) miR-1296-5p play a crucial role in breast cancer (BC), but the molecular mechanism is vague. Evidence showed that miR-1296-5p can activate tripartite motif-containing 14 (TRIM14). Clinical indications of eighty BC patients were collected and the circ_RPPH1 expression was detected using real-time quantitative PCR. MCF-7 and MDA-MB-231 cells were transfected with overexpression or knockdown of circ_RPPH1, miR-1296-5p, or TRIM14. Cell counting kit-8, cell cloning formation, wound healing, Transwell, and flow cytometry assays were performed to investigate the malignant phenotype of BC. The dual-luciferase reporter gene analyses were applied to reveal the interaction between these target genes. Subcutaneous tumorigenic model mice were established with circ_RPPH1 overexpression MDA-MB-231 cells in vivo; the tumor weight and volume, levels of miR-1296-5 and TRIM14 mRNA were measured. Western blot and immunohistochemistry were used to detect TRIM14 in cells and mice. Circ_RPPH1 levels were notably higher in BC patients and have been found to promote cell proliferation, invasion, and migration of BC cells. Circ_RPPH1 altered cell cycle and hindered apoptosis. Circ_RPPH1 knockdown or miR-1296-5p overexpression inhibited the malignant phenotype of BC. Furthermore, miR-1296-5p knockdown reversed circ_RPPH1's promotion effects on BC. Interestingly, TRIM14 overexpression counteracts the inhibitory effects of miR-1296-5p overexpression and circ_RPPH1 silencing on BC. Moreover, in BC tumor-bearing mice, circ_RPPH1 overexpression led to increased TRIM14 expression and facilitated tumor growth. Circ_RPPH1 enhanced BC progression through miR-1296-5p/TRIM14 axis, indicating its potential as a biomarker and therapeutic target in BC.

环状 RNA 核糖核酸酶 P RNA 成分 H1(circ_RPPH1)和 microRNA(miRNA)miR-1296-5p 在乳腺癌(BC)中起着至关重要的作用,但其分子机制尚不清楚。有证据表明,miR-1296-5p 能激活含三方基序 14(TRIM14)。研究人员收集了 80 例 BC 患者的临床指征,并使用实时定量 PCR 检测了 circ_RPPH1 的表达。用过表达或敲除 circ_RPPH1、miR-1296-5p 或 TRIM14 的方法转染 MCF-7 和 MDA-MB-231 细胞。进行了细胞计数试剂盒-8、细胞克隆形成、伤口愈合、Transwell 和流式细胞术检测,以研究 BC 的恶性表型。应用双荧光素酶报告基因分析揭示了这些靶基因之间的相互作用。用circ_RPPH1过表达的MDA-MB-231细胞建立皮下肿瘤模型小鼠,测量肿瘤的重量和体积、miR-1296-5和TRIM14 mRNA的水平。采用 Western 印迹和免疫组织化学方法检测细胞和小鼠中的 TRIM14。BC患者的Circ_RPPH1水平明显较高,研究发现它能促进BC细胞的增殖、侵袭和迁移。Circ_RPPH1会改变细胞周期并阻碍细胞凋亡。Circ_RPPH1敲除或miR-1296-5p过表达可抑制BC的恶性表型。此外,miR-1296-5p 的敲除逆转了 circ_RPPH1 对 BC 的促进作用。有趣的是,TRIM14 的过表达抵消了 miR-1296-5p 过表达和 circ_RPPH1 沉默对 BC 的抑制作用。此外,在BC肿瘤小鼠中,circ_RPPH1过表达会导致TRIM14表达增加,并促进肿瘤生长。circ_RPPH1通过miR-1296-5p/TRIM14轴促进了BC的进展,表明它有可能成为BC的生物标记物和治疗靶点。
{"title":"Circ_RPPH1 facilitates progression of breast cancer via miR-1296-5p/TRIM14 axis.","authors":"Jing Jiang, Shenghong Shi, Wei Zhang, Chao Li, Long Sun, Qidong Ge, Xujun Li","doi":"10.1080/15384047.2024.2360768","DOIUrl":"10.1080/15384047.2024.2360768","url":null,"abstract":"<p><p><i>Circular RNA Ribonuclease P</i> <i>RNA Component H1</i> (<i>circ_RPPH1</i>) and microRNA (miRNA) <i>miR-1296-5p</i> play a crucial role in breast cancer (BC), but the molecular mechanism is vague. Evidence showed that <i>miR-1296-5p</i> can activate <i>tripartite motif-containing 14</i> (<i>TRIM14</i>). Clinical indications of eighty BC patients were collected and the <i>circ_RPPH1</i> expression was detected using real-time quantitative PCR. MCF-7 and MDA-MB-231 cells were transfected with overexpression or knockdown of <i>circ_RPPH1</i>, <i>miR-1296-5p</i>, or <i>TRIM14</i>. Cell counting kit-8, cell cloning formation, wound healing, Transwell, and flow cytometry assays were performed to investigate the malignant phenotype of BC. The dual-luciferase reporter gene analyses were applied to reveal the interaction between these target genes. Subcutaneous tumorigenic model mice were established with <i>circ_RPPH1</i> overexpression MDA-MB-231 cells in vivo; the tumor weight and volume, levels of <i>miR-1296-5</i> and <i>TRIM14</i> mRNA were measured. Western blot and immunohistochemistry were used to detect TRIM14 in cells and mice. <i>Circ_RPPH1</i> levels were notably higher in BC patients and have been found to promote cell proliferation, invasion, and migration of BC cells. <i>Circ_RPPH1</i> altered cell cycle and hindered apoptosis. <i>Circ_RPPH1</i> knockdown or <i>miR-1296-5p</i> overexpression inhibited the malignant phenotype of BC. Furthermore, <i>miR-1296-5p</i> knockdown reversed <i>circ_RPPH1</i>'s promotion effects on BC. Interestingly, <i>TRIM14</i> overexpression counteracts the inhibitory effects of <i>miR-1296-5p</i> overexpression and <i>circ_RPPH1</i> silencing on BC. Moreover, in BC tumor-bearing mice, <i>circ_RPPH1</i> overexpression led to increased TRIM14 expression and facilitated tumor growth. <i>Circ_RPPH1</i> enhanced BC progression through <i>miR-1296-5p</i>/<i>TRIM14</i> axis, indicating its potential as a biomarker and therapeutic target in BC.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"25 1","pages":"2360768"},"PeriodicalIF":4.4,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11141472/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141178606","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain. 尼舍韦单抗免疫计划实施前家长对呼吸道合胞病毒的了解:西班牙一个自治区对免疫接种的态度。
IF 4.8 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-06-10 DOI: 10.1080/21645515.2024.2357439
Matilde Zornoza Moreno, Jaime Jesús Pérez Martín, Mª Cruz Gómez Moreno, Mª Pilar Ros Abellán

Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new preventive monoclonal antibody (MAb), nirsevimab, has been launched in the United States, Luxembourg, and France, and was recently approved to be given in a population-based manner throughout Spain. This study aimed to have a first pre-immunization insight into the Spanish parental knowledge about bronchiolitis, RSV, and nirsevimab immunization. Parents in Murcia with children <2 years of age up to the date of September 1, 2023, were selected to complete a questionnaire. The primary endpoint was the parental knowledge about bronchiolitis, RSV, and nirsevimab. A total of 3,217 responses were analyzed. The majority (95.8%) were aware of bronchiolitis. Meanwhile, 46.6% of the respondents knew about RSV, most of them only after the first child's birth. Information about RSV or bronchiolitis was mainly obtained from family members, with only 4.8% reporting having been informed by Health care Professionals (HCPs). Only 11.2% of respondents were aware of nirsevimab. Nonetheless, these were not entirely satisfied with the information received (score of 3.3 out of 5) and shared that HCPs should be the primary source of information. The present survey then highlights the need for better and more efficient educational strategies directed to all parents/legal guardians. It also sheds some light on the different factors that should be considered to improve awareness of RSV immunization to decrease its burden in Spain and beyond.

呼吸道合胞病毒(RSV)是幼儿下呼吸道感染的主要病因,也与大多数支气管炎和肺炎相关的住院治疗有关。一种新的预防性单克隆抗体(MAb)--nirsevimab 已在美国、卢森堡和法国上市,最近又获准在西班牙全国范围内以人群为基础使用。这项研究的目的是在免疫前首次了解西班牙家长对支气管炎、RSV 和 nirsevimab 免疫的认识。穆尔西亚有孩子的家长
{"title":"Parental knowledge on the respiratory syncytial virus before the nirsevimab immunization program: Attitudes toward immunization in an autonomous community of Spain.","authors":"Matilde Zornoza Moreno, Jaime Jesús Pérez Martín, Mª Cruz Gómez Moreno, Mª Pilar Ros Abellán","doi":"10.1080/21645515.2024.2357439","DOIUrl":"10.1080/21645515.2024.2357439","url":null,"abstract":"<p><p>Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in young children and associated with most bronchiolitis- and pneumonia-related hospitalizations. A new preventive monoclonal antibody (MAb), nirsevimab, has been launched in the United States, Luxembourg, and France, and was recently approved to be given in a population-based manner throughout Spain. This study aimed to have a first pre-immunization insight into the Spanish parental knowledge about bronchiolitis, RSV, and nirsevimab immunization. Parents in Murcia with children <2 years of age up to the date of September 1, 2023, were selected to complete a questionnaire. The primary endpoint was the parental knowledge about bronchiolitis, RSV, and nirsevimab. A total of 3,217 responses were analyzed. The majority (95.8%) were aware of bronchiolitis. Meanwhile, 46.6% of the respondents knew about RSV, most of them only after the first child's birth. Information about RSV or bronchiolitis was mainly obtained from family members, with only 4.8% reporting having been informed by Health care Professionals (HCPs). Only 11.2% of respondents were aware of nirsevimab. Nonetheless, these were not entirely satisfied with the information received (score of 3.3 out of 5) and shared that HCPs should be the primary source of information. The present survey then highlights the need for better and more efficient educational strategies directed to all parents/legal guardians. It also sheds some light on the different factors that should be considered to improve awareness of RSV immunization to decrease its burden in Spain and beyond.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2357439"},"PeriodicalIF":4.8,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168215/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141301904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma. Sirtuin1(sirt1)调节糖酵解途径并降低顺铂化疗对食管鳞状细胞癌的敏感性。
IF 4.4 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-06-12 DOI: 10.1080/15384047.2024.2365449
Xuewen Yang, Shisen Li, Chunsheng Xu, Shushang Liu, Xiang Zhang, Bo Lian, Mengbin Li

We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced in vivo ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity.

我们旨在评估sirtuin1(sirt1)对ESCC顺铂化疗敏感性的影响。我们使用 ESCC 细胞消融 sirt1 来建立异种移植小鼠肿瘤模型,然后检测肿瘤体积。sirt1在ESCC患者和细胞中显著过度表达。此外,sirt1的敲除提高了ESCC对顺铂的敏感性。此外,糖酵解与 ESCC 细胞对顺铂的化疗耐药性有关。此外,sirt1通过HK2增加了ESCC细胞对顺铂的化疗敏感性。Sirt1增强了体内ESCC对顺铂的化疗敏感性。总之,这些研究结果表明,sirt1的敲除调节了糖酵解途径,提高了ESCC的化疗敏感性。
{"title":"Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.","authors":"Xuewen Yang, Shisen Li, Chunsheng Xu, Shushang Liu, Xiang Zhang, Bo Lian, Mengbin Li","doi":"10.1080/15384047.2024.2365449","DOIUrl":"10.1080/15384047.2024.2365449","url":null,"abstract":"<p><p>We aimed to evaluate the influence of sirtuin1 (sirt1) on the ESCC chemotherapeutic sensitivity to cisplatin. We used ESCC cell ablation sirt1 for establishing a xenograft mouse tumor model. The tumor volume was then detected. sirt1 was over-expressed significantly in ESCC patients and cells. Moreover, sirt1 knockdown raised ESCC sensitivity to cisplatin. Besides, glycolysis was associated with ESCC cell chemotherapy resistance to cisplatin. Furthermore, sirt1 increased ESCC cells' cisplatin chemosensitivity through HK2. Sirt1 enhanced <i>in vivo</i> ESCC chemosensitivity to cisplatin. Overall, these findings suggested that sirt1 knockdown regulated the glycolysis pathway and raised the ESCC chemotherapeutic sensitivity.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"25 1","pages":"2365449"},"PeriodicalIF":4.4,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11174053/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 vaccine hesitancy and intentions among parents of children with mental and behavioral disorders. 有精神和行为障碍儿童的家长对 COVID-19 疫苗的犹豫和意向。
IF 4.1 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-10-16 DOI: 10.1080/21645515.2024.2412385
Mohamed Adil Shah Khoodoruth, Sami Ouanes, Kristian Somintac, Shaima Gulistan, Asieh Dehwari, Widaad Nuzhah Chut-Kai Khoodoruth, Mohammed Nasser Alamri, Majid Alabdulla, Yasser Saeed Khan

Parent vaccine hesitancy (PVH) remains a significant public health concern, particularly emphasized during the COVID-19 pandemic. This study investigates PVH among parents of children with various psychiatric and neurodevelopmental conditions, such as attention deficit hyperactivity disorder (ADHD), anxiety disorders, and behavioral disturbances, extending previous research focused on autism spectrum disorder (ASD). We examined PVH in children aged 5-11 years with psychiatric and behavioral disorders excluding ASD. A cross-sectional questionnaire-based analysis was conducted in Qatar, involving 244 parents of neurodiverse children and 245 parents of neurotypical children as controls. The Parent Attitudes about Childhood Vaccines (PACV) survey assessed PVH. Results indicated a significantly higher prevalence of vaccine hesitancy among parents of children with psychiatric disorders (54.1%, 95% CI [47.8%, 60.4%], n = 132) compared to controls (11.7%, 95% CI [7.5%, 16.0%], n = 26), p < .001. The PACV total score was significantly higher in parents of children with a mental disorder. Higher education among parents and lower PACV scores significantly influenced the intent to vaccinate against COVID-19. Tailored interventions by child and adolescent mental healthcare professionals, such as harnessing artificial intelligence to fight disinformation, are crucial to addressing vaccine hesitancy, enhancing acceptance, and improving outcomes for children with psychiatric disorders.

家长对疫苗犹豫不决(PVH)仍然是一个重要的公共卫生问题,在 COVID-19 大流行期间尤为突出。本研究调查了患有注意力缺陷多动障碍 (ADHD)、焦虑症和行为障碍等各种精神和神经发育疾病的儿童的家长的疫苗接种犹豫症,并扩展了之前以自闭症谱系障碍 (ASD) 为重点的研究。我们对患有精神和行为障碍(不包括自闭症谱系障碍)的 5-11 岁儿童的 PVH 进行了研究。我们在卡塔尔进行了一项基于横断面问卷的分析,其中包括 244 名神经多样化儿童的家长和 245 名神经典型儿童的家长作为对照。家长对儿童疫苗的态度(PACV)调查对 PVH 进行了评估。结果表明,与对照组(11.7%,95% CI [7.5%,16.0%],n = 26)相比,患有精神障碍儿童的家长(54.1%,95% CI [47.8%,60.4%],n = 132)的疫苗犹豫率明显更高,p
{"title":"COVID-19 vaccine hesitancy and intentions among parents of children with mental and behavioral disorders.","authors":"Mohamed Adil Shah Khoodoruth, Sami Ouanes, Kristian Somintac, Shaima Gulistan, Asieh Dehwari, Widaad Nuzhah Chut-Kai Khoodoruth, Mohammed Nasser Alamri, Majid Alabdulla, Yasser Saeed Khan","doi":"10.1080/21645515.2024.2412385","DOIUrl":"https://doi.org/10.1080/21645515.2024.2412385","url":null,"abstract":"<p><p>Parent vaccine hesitancy (PVH) remains a significant public health concern, particularly emphasized during the COVID-19 pandemic. This study investigates PVH among parents of children with various psychiatric and neurodevelopmental conditions, such as attention deficit hyperactivity disorder (ADHD), anxiety disorders, and behavioral disturbances, extending previous research focused on autism spectrum disorder (ASD). We examined PVH in children aged 5-11 years with psychiatric and behavioral disorders excluding ASD. A cross-sectional questionnaire-based analysis was conducted in Qatar, involving 244 parents of neurodiverse children and 245 parents of neurotypical children as controls. The Parent Attitudes about Childhood Vaccines (PACV) survey assessed PVH. Results indicated a significantly higher prevalence of vaccine hesitancy among parents of children with psychiatric disorders (54.1%, 95% CI [47.8%, 60.4%], <i>n</i> = 132) compared to controls (11.7%, 95% CI [7.5%, 16.0%], <i>n</i> = 26), <i>p</i> < .001. The PACV total score was significantly higher in parents of children with a mental disorder. Higher education among parents and lower PACV scores significantly influenced the intent to vaccinate against COVID-19. Tailored interventions by child and adolescent mental healthcare professionals, such as harnessing artificial intelligence to fight disinformation, are crucial to addressing vaccine hesitancy, enhancing acceptance, and improving outcomes for children with psychiatric disorders.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2412385"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11486274/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478671","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study. 针对 COVID-19 的改良 mRNA 脂质纳米粒子候选疫苗的安全性和免疫原性:1期剂量递增研究的结果。
IF 4.1 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-10-18 DOI: 10.1080/21645515.2024.2408863
Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte

This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 years previously vaccinated with ≥ 2 doses of an mRNA COVID-19 vaccine received CV0501 doses ranging from 12 to 200 μg. After assessment of safety and immunogenicity of the 12 μg dose in 30 adults, 30 adults ≤ 64 years were randomized to receive either a 3 or 6 μg dose. Solicited adverse events (AEs) were collected for 7 days, unsolicited AEs for 28 days, and serious AEs (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs) until day (D) 181 post-vaccination. Serum neutralizing titers specific to SARS-CoV-2 BA.1, wild-type, Delta, and additional Omicron subvariants were assessed at D1, D15, D29, D91, and D181. Of 180 vaccinated participants (mean age: 49.3 years; 57.8% women), 70.6% had prior SARS-CoV-2 infection. Most solicited local (98.1%) and systemic (96.7%) AEs were of mild-to-moderate severity; the most common were injection site pain (57.5%; 33.3-73.3% across groups) and myalgia (36.9%; 13.3-56.7%). Unsolicited AEs were reported by 14.4% (6.7-26.7%) of participants (mild-to-moderate severity in 88.5% of the participants). Three participants (1.7%) reported SAEs, 16.7% (6.7-30.0%) reported MAAEs, and 8.3% (0.0-13.3%) reported AESIs (15 COVID-19 cases), none related to vaccination. Geometric means of serum neutralizing titers increased from baseline to D15 and D29 (dose-dependent), and then decreased over time. The safety and immunogenicity results supported advancement to a phase 2 trial.

这项1期、开放标签、剂量递增、多中心研究(NCT05477186)评估了编码SARS-CoV-2 Omicron BA.1尖峰蛋白的mRNA COVID-19疫苗(CV0501)加强剂量的安全性和免疫原性。年龄≥ 18 岁、曾接种过≥ 2 剂 mRNA COVID-19 疫苗的参与者接种的 CV0501 剂量为 12 μg 至 200 μg。在对 30 名成人接种 12 μg 剂量的安全性和免疫原性进行评估后,30 名年龄在 64 岁以下的成人被随机分配接种 3 或 6 μg 剂量。在接种后的第181天(D)前,收集了7天的主动不良事件(AEs)、28天的非主动不良事件以及严重不良事件(SAEs)、医疗护理不良事件(MAAEs)和特别关注不良事件(AESIs)。在第 1 天、第 15 天、第 29 天、第 91 天和第 181 天对 SARS-CoV-2 BA.1、野生型、Delta 和其他 Omicron 亚变体的特异性血清中和滴度进行了评估。在 180 名接种者(平均年龄:49.3 岁;57.8% 为女性)中,70.6% 曾感染过 SARS-CoV-2。大多数主动提出的局部(98.1%)和全身(96.7%)AE 为轻度至中度;最常见的是注射部位疼痛(57.5%;各组别为 33.3-73.3%)和肌痛(36.9%;13.3-56.7%)。14.4%(6.7-26.7%)的参与者报告了非主动发生的不良反应(88.5%的参与者为轻度至中度)。三名参与者(1.7%)报告了 SAE,16.7%(6.7-30.0%)报告了 MAAE,8.3%(0.0-13.3%)报告了 AESI(15 例 COVID-19),但均与疫苗接种无关。血清中和滴度的几何平均值从基线上升到D15和D29(剂量依赖性),然后随着时间的推移而下降。安全性和免疫原性结果支持进入第二阶段试验。
{"title":"Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.","authors":"Brandon J Essink, Craig Shapiro, Marie Grace Dawn Isidro, Paul Bradley, Antoinette Pragalos, Mark Bloch, Joel Santiaguel, Melchor Victor Frias, Spiros Miyakis, Margarida Alves de Mesquita, Stefano Berrè, Charlotte Servais, Natasha Waugh, Claudia Hoffmann, Emna Baba, Oliver Schönborn-Kellenberger, Olaf-Oliver Wolz, Sven D Koch, Tapiwa Ganyani, Philippe Boutet, Philipp Mann, Stefan O Mueller, Roshan Ramanathan, Martin Robert Gaudinski, Nicolas Vanhoutte","doi":"10.1080/21645515.2024.2408863","DOIUrl":"10.1080/21645515.2024.2408863","url":null,"abstract":"<p><p>This phase 1, open-label, dose-escalation, multi-center study (NCT05477186) assessed the safety and immunogenicity of a booster dose of an mRNA COVID-19 vaccine (CV0501) encoding the SARS-CoV-2 Omicron BA.1 spike protein. Participants aged ≥ 18 years previously vaccinated with ≥ 2 doses of an mRNA COVID-19 vaccine received CV0501 doses ranging from 12 to 200 μg. After assessment of safety and immunogenicity of the 12 μg dose in 30 adults, 30 adults ≤ 64 years were randomized to receive either a 3 or 6 μg dose. Solicited adverse events (AEs) were collected for 7 days, unsolicited AEs for 28 days, and serious AEs (SAEs), medically attended AEs (MAAEs), and AEs of special interest (AESIs) until day (D) 181 post-vaccination. Serum neutralizing titers specific to SARS-CoV-2 BA.1, wild-type, Delta, and additional Omicron subvariants were assessed at D1, D15, D29, D91, and D181. Of 180 vaccinated participants (mean age: 49.3 years; 57.8% women), 70.6% had prior SARS-CoV-2 infection. Most solicited local (98.1%) and systemic (96.7%) AEs were of mild-to-moderate severity; the most common were injection site pain (57.5%; 33.3-73.3% across groups) and myalgia (36.9%; 13.3-56.7%). Unsolicited AEs were reported by 14.4% (6.7-26.7%) of participants (mild-to-moderate severity in 88.5% of the participants). Three participants (1.7%) reported SAEs, 16.7% (6.7-30.0%) reported MAAEs, and 8.3% (0.0-13.3%) reported AESIs (15 COVID-19 cases), none related to vaccination. Geometric means of serum neutralizing titers increased from baseline to D15 and D29 (dose-dependent), and then decreased over time. The safety and immunogenicity results supported advancement to a phase 2 trial.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2408863"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492660/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142478693","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Parent and family characteristics associated with reported pediatric influenza vaccination in a sample of Canadian digital vaccination platform users. An exploratory, cross-sectional study in the 2018-2019 influenza season. 加拿大数字疫苗接种平台用户样本中与所报告的小儿流感疫苗接种相关的家长和家庭特征。2018-2019流感季节的一项探索性横断面研究。
IF 4.1 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-07-22 DOI: 10.1080/21645515.2024.2378580
Katherine Atkinson, Blaise Ntacyabukura, Steven Hawken, Ziad El-Khatib, Lucie Laflamme, Kumanan Wilson

Seasonal vaccination remains one of the best interventions to prevent morbidity and mortality from influenza in children. Understanding the characteristics of parents who vaccinate their children can inform communication strategies to encourage immunization. Using a cross-sectional study, we described parental characteristics of people who reported vaccinating their children against influenza during 2018/2019 in a cohort of Canadian digital immunization record users. Data was collected from a free, Pan-Canadian digital vaccination tool, CANImmunize. Eligible accounts contained at least one parental and one "child/dependent" record. Each parental characteristic (gender, age, family size, etc) was tested for association with pediatric influenza vaccination, and a multivariate logistic regression model was fit. A total of 6,801 CANImmunize accounts met inclusion criteria. After collapsing the dataset, the final sample contained 11,381 unique dyads. Influenza vaccination was reported for 32.3% of the children and 42.0% of the parents. In the multivariate logistic regression analysis, parents receiving the seasonal influenza vaccine were most strongly associated with reporting pediatric influenza vaccination (OR 17.05, 95% CI 15.08, 19.28). Having a larger family size and fewer transactions during the study period was associated with not reporting pediatric influenza vaccination. While there are several limitations to this large-scale study, these results can help inform future research in the area. Digital technologies may provide a unique and valuable source of vaccine coverage data and to explore associations between individual characteristics and immunization behavior. Policy makers considering digital messaging may want to tailor their efforts based on parental characteristics to further improve pediatric seasonal influenza vaccine uptake.

接种季节性疫苗仍是预防儿童流感发病和死亡的最佳干预措施之一。了解为子女接种疫苗的父母的特征可以为鼓励免疫接种的沟通策略提供参考。通过一项横断面研究,我们描述了加拿大数字免疫接种记录用户队列中报告在 2018/2019 年期间为子女接种流感疫苗的父母的特征。数据收集自免费的泛加拿大数字疫苗接种工具 CANImmunize。符合条件的账户至少包含一条父母记录和一条 "儿童/家属 "记录。对父母的每个特征(性别、年龄、家庭规模等)与小儿流感疫苗接种的关联性进行了测试,并拟合了一个多变量逻辑回归模型。共有 6801 个 CANImmunize 账户符合纳入标准。对数据集进行整理后,最终样本包含 11,381 个独特的二人组。有 32.3% 的儿童和 42.0% 的家长接种了流感疫苗。在多变量逻辑回归分析中,接种季节性流感疫苗的父母与报告接种小儿流感疫苗的关系最为密切(OR 17.05,95% CI 15.08,19.28)。在研究期间,家庭人口较多和交易次数较少与未报告接种小儿流感疫苗有关。虽然这项大规模研究存在一些局限性,但这些结果有助于为该领域的未来研究提供信息。数字技术可以提供独特而宝贵的疫苗覆盖率数据来源,并探索个人特征与免疫接种行为之间的关联。考虑使用数字信息的政策制定者可能希望根据家长的特征来调整他们的工作,以进一步提高小儿季节性流感疫苗的接种率。
{"title":"Parent and family characteristics associated with reported pediatric influenza vaccination in a sample of Canadian digital vaccination platform users. An exploratory, cross-sectional study in the 2018-2019 influenza season.","authors":"Katherine Atkinson, Blaise Ntacyabukura, Steven Hawken, Ziad El-Khatib, Lucie Laflamme, Kumanan Wilson","doi":"10.1080/21645515.2024.2378580","DOIUrl":"https://doi.org/10.1080/21645515.2024.2378580","url":null,"abstract":"<p><p>Seasonal vaccination remains one of the best interventions to prevent morbidity and mortality from influenza in children. Understanding the characteristics of parents who vaccinate their children can inform communication strategies to encourage immunization. Using a cross-sectional study, we described parental characteristics of people who reported vaccinating their children against influenza during 2018/2019 in a cohort of Canadian digital immunization record users. Data was collected from a free, Pan-Canadian digital vaccination tool, CANImmunize. Eligible accounts contained at least one parental and one \"child/dependent\" record. Each parental characteristic (gender, age, family size, etc) was tested for association with pediatric influenza vaccination, and a multivariate logistic regression model was fit. A total of 6,801 CANImmunize accounts met inclusion criteria. After collapsing the dataset, the final sample contained 11,381 unique dyads. Influenza vaccination was reported for 32.3% of the children and 42.0% of the parents. In the multivariate logistic regression analysis, parents receiving the seasonal influenza vaccine were most strongly associated with reporting pediatric influenza vaccination (OR 17.05, 95% CI 15.08, 19.28). Having a larger family size and fewer transactions during the study period was associated with not reporting pediatric influenza vaccination. While there are several limitations to this large-scale study, these results can help inform future research in the area. Digital technologies may provide a unique and valuable source of vaccine coverage data and to explore associations between individual characteristics and immunization behavior. Policy makers considering digital messaging may want to tailor their efforts based on parental characteristics to further improve pediatric seasonal influenza vaccine uptake.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2378580"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141735408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα. WYC-209 通过 RARα 下调 WNT4,从而抑制 GC 的恶性发展。
IF 3.6 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-01-04 DOI: 10.1080/15384047.2023.2299288
Zhenyuan Qian, Wenfa Lin, Xufan Cai, Jianzhang Wu, Kun Ke, Zaiyuan Ye, Fang Wu

Gastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins and mRNA. RNA-seq and enrichment analyses were conducted for the differentially expressed genes and enriched biological processes and pathways. The rescue experiments were carried out for further validation. Besides, we constructed xenograft model to confirm the effect of WYC-209 in vivo. The dual-luciferase reporter and Chromatin immunoprecipitation were implemented to confirm the underlying mechanism. WYC-209 exerted excellent anti-cancer effects both in vitro and in vivo. Based on RNA-seq and enrichment analyses, we found that Wnt family member 4 (WNT4) was significantly down-regulated. More importantly, WNT4 overexpression breached the inhibitory effect of WYC-209 on GC progression. Mechanically, WYC-209 significantly promoted the binding between retinoic acid receptor α (RARα) and WNT4 promoter. WYC-209 exerts anti-tumor effects in GC by down-regulating the expression of WNT4 via RARα.

胃癌(GC)一直是全球主要的健康负担,但由于其多药耐药性,有前景的化疗药物较少。有报道称,WYC-209 可抑制肿瘤繁殖细胞的生长和转移,但对 GC 的影响尚未探究。为了研究 WYC-209 对 GC 细胞的增殖、集落生长和移动性的影响,我们进行了 MTT、集落形成和透孔试验。采用 Western 印迹和 qRT-PCR 检测蛋白质和 mRNA 的表达。对差异表达基因和富集的生物过程和通路进行了 RNA-seq 和富集分析。为了进一步验证,我们还进行了拯救实验。此外,我们还构建了异种移植模型来证实 WYC-209 在体内的作用。我们还利用双荧光素酶报告和染色质免疫沉淀来证实其潜在机制。WYC-209在体外和体内都发挥了很好的抗癌作用。基于 RNA-seq 和富集分析,我们发现 Wnt 家族成员 4(WNT4)被显著下调。更重要的是,WNT4的过表达破坏了WYC-209对GC进展的抑制作用。在机制上,WYC-209 能明显促进视黄酸受体α(RARα)与 WNT4 启动子的结合。WYC-209 通过 RARα 下调 WNT4 的表达,从而在 GC 中发挥抗肿瘤作用。
{"title":"WYC-209 inhibited GC malignant progression by down-regulating WNT4 through RARα.","authors":"Zhenyuan Qian, Wenfa Lin, Xufan Cai, Jianzhang Wu, Kun Ke, Zaiyuan Ye, Fang Wu","doi":"10.1080/15384047.2023.2299288","DOIUrl":"10.1080/15384047.2023.2299288","url":null,"abstract":"<p><p>Gastric cancer (GC) has been a major health burden all over the world but there are fewer promising chemotherapeutic drugs due to its multidrug resistance. It has been reported that WYC-209 suppresses the growth and metastasis of tumor-repopulating cells but the effect on GC was not explored. MTT, colony formation, and transwell assays were performed to examine the effects of WYC-209 on the proliferation, colony growth, and mobility of GC cells. Western blotting and qRT-PCR were used to detect the expression of proteins and mRNA. RNA-seq and enrichment analyses were conducted for the differentially expressed genes and enriched biological processes and pathways. The rescue experiments were carried out for further validation. Besides, we constructed xenograft model to confirm the effect of WYC-209 in vivo. The dual-luciferase reporter and Chromatin immunoprecipitation were implemented to confirm the underlying mechanism. WYC-209 exerted excellent anti-cancer effects both in vitro and in vivo. Based on RNA-seq and enrichment analyses, we found that Wnt family member 4 (WNT4) was significantly down-regulated. More importantly, WNT4 overexpression breached the inhibitory effect of WYC-209 on GC progression. Mechanically, WYC-209 significantly promoted the binding between retinoic acid receptor α (RARα) and WNT4 promoter. WYC-209 exerts anti-tumor effects in GC by down-regulating the expression of WNT4 via RARα.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"25 1","pages":"2299288"},"PeriodicalIF":3.6,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10773637/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139097377","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Individual predictors of vaccine hesitancy in the Italian post COVID-19 pandemic era. 意大利后 COVID-19 大流行时代疫苗犹豫不决的个体预测因素。
IF 4.1 3区 材料科学 Q2 CHEMISTRY, PHYSICAL Pub Date : 2024-12-31 Epub Date: 2024-01-30 DOI: 10.1080/21645515.2024.2306677
Carmelo M Vicario, Massimo Mucciardi, Giulia Faraone, Chiara Lucifora, Hannah M Schade, Alessandra Falzone, Mohammad A Salehinejad, Giuseppe Craparo, Michael A Nitsche

A wide range of survey studies have explored vaccination hesitancy/resistance during the COVID-19 pandemic and provided evidence that this can be explained by several individual variables from the ideological, clinical, and socio-affective domain. However, evidence about which individual variables predict vaccine hesitancy in the post-pandemic state of COVID-19 is meager. We administered a battery of questionnaires to a group of 120 Italian participants with high and low scores on the adult vaccine hesitancy scale (aVHS) to investigate the predictive role of ideological (i.e. political orientation), clinical (i.e. anxiety, interoceptive accuracy), and socio-affective (i.e. alexithymia, disgust sensitivity/propensity, empathy) variables on vaccine hesitancy/resistance. This study provides evidence that lower interoceptive awareness and cognitive empathy are predictors of a greater hesitancy to get vaccinated in the post-pandemic COVID-19 state.

许多调查研究都探讨了 COVID-19 大流行期间的疫苗接种犹豫/抵触情绪,并提供了证据表明这可以用意识形态、临床和社会情感领域的几个个体变量来解释。然而,关于哪些个体变量可预测 COVID-19 大流行后的疫苗接种犹豫不决的证据却很少。我们对 120 名在成人疫苗犹豫量表(aVHS)上得分较高和较低的意大利参与者进行了一系列问卷调查,以研究意识形态(即政治倾向)、临床(即焦虑、感知间准确性)和社会情感(即情感障碍、厌恶敏感性/倾向、移情)变量对疫苗犹豫/抵抗的预测作用。本研究提供的证据表明,在 COVID-19 大流行后的状态下,较低的感知间意识和认知移情是更犹豫是否接种疫苗的预测因素。
{"title":"Individual predictors of vaccine hesitancy in the Italian post COVID-19 pandemic era.","authors":"Carmelo M Vicario, Massimo Mucciardi, Giulia Faraone, Chiara Lucifora, Hannah M Schade, Alessandra Falzone, Mohammad A Salehinejad, Giuseppe Craparo, Michael A Nitsche","doi":"10.1080/21645515.2024.2306677","DOIUrl":"10.1080/21645515.2024.2306677","url":null,"abstract":"<p><p>A wide range of survey studies have explored vaccination hesitancy/resistance during the COVID-19 pandemic and provided evidence that this can be explained by several individual variables from the ideological, clinical, and socio-affective domain. However, evidence about which individual variables predict vaccine hesitancy in the post-pandemic state of COVID-19 is meager. We administered a battery of questionnaires to a group of 120 Italian participants with high and low scores on the adult vaccine hesitancy scale (aVHS) to investigate the predictive role of ideological (i.e. political orientation), clinical (i.e. anxiety, interoceptive accuracy), and socio-affective (i.e. alexithymia, disgust sensitivity/propensity, empathy) variables on vaccine hesitancy/resistance. This study provides evidence that lower interoceptive awareness and cognitive empathy are predictors of a greater hesitancy to get vaccinated in the post-pandemic COVID-19 state.</p>","PeriodicalId":4,"journal":{"name":"ACS Applied Energy Materials","volume":"20 1","pages":"2306677"},"PeriodicalIF":4.1,"publicationDate":"2024-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10829816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139576922","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"材料科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
ACS Applied Energy Materials
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1